Gina Chapman - Sep 18, 2024 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role
President & CEO, Director
Signature
/s/ Halley Gilbert, as attorney-in-fact for Gina Chapman
Stock symbol
CRGX
Transactions as of
Sep 18, 2024
Transactions value $
-$203,222
Form type
4
Date filed
9/20/2024, 05:24 PM
Previous filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRGX Common Stock Options Exercise $36K +7.17K +6.9% $5.03 111K Sep 18, 2024 Direct
transaction CRGX Common Stock Sale -$180K -7.17K -6.45% $25.09 104K Sep 18, 2024 Direct F1, F2
transaction CRGX Common Stock Options Exercise $15K +2.98K +2.86% $5.03 107K Sep 19, 2024 Direct
transaction CRGX Common Stock Sale -$74.5K -2.98K -2.78% $25.03 104K Sep 19, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRGX Stock Option (Right to Buy) Options Exercise $0 -7.17K -1.28% $0.00 552K Sep 18, 2024 Common Stock 7.17K $5.03 Direct F4
transaction CRGX Stock Option (Right to Buy) Options Exercise $0 -2.98K -0.54% $0.00 550K Sep 19, 2024 Common Stock 2.98K $5.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 25, 2024.
F2 This transaction was executed in multiple trades in prices ranging from $25.00 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $25.00 to $25.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.